BMY News and Press, Bristol-Myers Squibb Company From 04/20/24

2024-04-20 12:03:00 ET Summary abrdn Healthcare Opportunities Fund (THQ) offers a high dividend yield of 11.3% and exposure to diverse subsectors of the healthcare industry. The fund outperforms its peers, abrdn World Healthcare Fund (THW) and BlackRock's Health Sciences Trust (BM...

2024-04-20 05:23:00 ET What's better than a high-yielding dividend stock? A high-yielding dividend stock that's trading at a dirt-cheap price. As long as the underlying business is in strong shape, buying a cheap dividend stock can help maximize your long-term profits as you benefit from ...

2024-04-19 13:49:43 ET Summary SELLAS Life Sciences Group, Inc. is a late-stage biotech company with a leading drug candidate, Galinpepimut-S, or GPS, that has a 44% probability of success and a potential 9x return. GPS is an immunotherapy drug targeting the Wilms Tumor 1 antigen,...

2024-04-19 08:15:00 ET The healthcare industry can be a good place to invest for the long term. Demand for healthcare is only going to rise as the number of seniors goes up, and general population growth will also mean more of a need for devices, drugs, and healthcare services. Ev...

2024-04-19 06:13:03 ET More on Bristol-Myers Squibb, Gilead, etc. Johnson & Johnson: Buy This Bargain Before It's Gone Bristol-Myers Squibb: Market Pessimism Won't Last Forever Johnson & Johnson (JNJ) Q1 2024 Earnings Call Transcript FDA approves Alvo...

2024-04-18 08:15:07 ET Wells Fargo analyst issues EQUAL-WEIGHT recommendation for BMY on April 18, 2024 06:18AM ET. The previous analyst recommendation was Equal-Weight. BMY was trading at $47.84 at issue of the analyst recommendation. The overall analyst consensus : HOL...

2024-04-18 07:28:39 ET Summary On April 16, Johnson & Johnson released financial results for the first three months of 2024, which were within my expectations. Tecvayli sales were $133 million in the first quarter of 2024, up 111% year over year. Despite increased competit...

2024-04-18 07:00:23 ET More on AbbVie AbbVie: Through Humira's Crisis Towards Solid Growth AbbVie: Great To Be Proven Wrong - Still Not A Buy AbbVie: Bulletproof Fundamentals CVS favors Humira copycats hurting AbbVie’s market share: Evercore Ab...

2024-04-17 11:30:43 ET Summary Bristol-Myers Squibb Company stock continues to struggle at a four-year low. Revlimid's revenue decline and increased competition from generics pose significant challenges for the company. Bristol-Myers Squibb needs to convince investors that its...

2024-04-17 09:30:00 ET Great dividend stocks don't always have particularly high yields. Still, it's nice to see a solid income stock that boasts one that's higher than average. And if this company can reward its shareholders by constantly raising its payouts -- and if it can do so for long...